| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Bacterial cell wall synthesis or essential bacterial enzymes. While the exact molecular target of Antibacterial agent 19 is not specified, its antibacterial activity suggests it may target bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis pathways, based on the structural features of its fluoroquinolone-like core.
|
|---|---|
| ln Vitro |
Antibacterial agent 19 demonstrates potent in vitro antibacterial activity. It exhibits strong activity against K. pneumoniae, (M-R)S. aureus, and (M-R,V-R)S. aureus, with minimum inhibitory concentrations (MICs) of 0.022 mg/mL for K. pneumoniae and (M-R)S. aureus, and 0.045 mg/mL for (M-R,V-R)S. aureus.
|
| ln Vivo |
No specific in vivo activity data has been reported. Based on its potent antibacterial activity, it would be evaluated in animal models of bacterial infection such as murine thigh infection models or sepsis models. It is expected to reduce bacterial burden and improve survival rates.
|
| Enzyme Assay |
Not applicable. As the specific molecular target has not been identified, no cell-free binding or enzymatic assay has been reported. The compound's antibacterial activity has been characterized through bacterial culture-based MIC assays, which evaluate growth inhibition in whole bacterial cells rather than isolated enzyme systems.
|
| Cell Assay |
For in vitro antibacterial evaluation, clinical isolates of K. pneumoniae, methicillin-resistant S. aureus (MRSA), and vancomycin-resistant S. aureus (VRSA) are cultured in appropriate media (e.g., Mueller-Hinton broth). Bacterial suspensions are adjusted to 0.5 McFarland standard and inoculated into 96-well plates containing serial dilutions of Antibacterial agent 19 (0.001-100 mg/mL). After 18-24 hours of incubation at 37degC, the minimum inhibitory concentration (MIC) is determined as the lowest concentration that prevents visible bacterial growth. The MIC values are recorded as 0.022 mg/mL for K. pneumoniae and (M-R)S. aureus, and 0.045 mg/mL for (M-R,V-R)S. aureus.
|
| Animal Protocol |
No specific in vivo animal study protocols are documented. A typical protocol for evaluating a novel antibacterial compound would involve infecting mice (e.g., BALB/c or ICR) with a lethal dose of K. pneumoniae or S. aureus via intraperitoneal or intravenous injection. Two hours post-infection, Antibacterial agent 19 would be administered at doses ranging from 1-50 mg/kg via intravenous or intraperitoneal injection. Survival rates and bacterial burden in blood and organs would be assessed 24-72 hours post-treatment.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data has been reported. As a small molecule with a molecular weight of 338.31 g/mol and a molecular formula C16H16F2N2O4, Antibacterial agent 19 likely has moderate lipophilicity and may be amenable to oral administration. Its ADME properties require experimental determination.
|
| Toxicity/Toxicokinetics |
No toxicity data has been reported. As a research chemical with antibacterial activity, comprehensive toxicological evaluation has not been conducted. Standard chemical safety precautions should be used when handling this compound. It is not recommended for human or veterinary use.
|
| References |
[1]. Sunduru N, et, al. Synthesis and antibacterial evaluation of novel 8-fluoro Norfloxacin derivatives as potential probes for methicillin and vancomycin-resistant Staphylococcus aureus. Eur J Med Chem. 2011 Apr;46(4):1232-44.
|
| Additional Infomation |
Antibacterial agent 19 has the molecular formula C16H16F2N2O4 and a molecular weight of 338.31. The compound contains a fluorine-substituted aromatic ring and a morpholine substituent. The compound is also known as Oprea1_738334, MLS000675049, and SCHEMBL311638. It is strictly a research chemical for antibacterial and anti-infective studies. It is not approved for clinical therapy.
|
| Exact Mass |
338.108
|
|---|---|
| CAS # |
79660-59-6
|
| PubChem CID |
1505698
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
550
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCOCC3)F)C(=O)O
|
| InChi Key |
DASUZCVFUIROFI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H16F2N2O4/c1-2-19-8-10(16(22)23)15(21)9-7-11(17)14(12(18)13(9)19)20-3-5-24-6-4-20/h7-8H,2-6H2,1H3,(H,22,23)
|
| Chemical Name |
1-ethyl-6,8-difluoro-7-morpholin-4-yl-4-oxoquinoline-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 1.82 mg/mL (5.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
